Multiple Sclerosis Drugs Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2024-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 7.9% from 2024-2032

Unit

Value (USD Billion)

Segmentation

By Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Others

By Route of Administration

• Oral
• Injection
• Intramuscular
• Subcutaneous
• Intravenous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (By Drug Class, by Route of Administration, by Distribution Channel, and by Country)
• U.S.
• Canada
• Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
• U.K.
• Germany
• France
• Italy
• Spain
• Scandinavia
• Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
• Japan
• China
• India
• Australia
• Southeast Asia
• Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
• South Africa
• GCC
• Rest of the Middle East & Africa